Baqsimi™ (glucagon) nasal powder


This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BAQSIMI™ (glucagon) nasal powder: Use of Both Baqsimi and Glucagon For Injection in Single Hypoglycemic Event

There have been no studies conducted on the use of both Baqsimi (glucagon nasal powder) and glucagon for injection to treat a single, severe hypoglycemic event.

Detailed Information

The recommended dose of Baqsimi is 3 mg administered as one actuation of the intranasal device into one nostril.1

Call for emergency assistance immediately after administering the dose.1

If there has been no response after 15 minutes, an additional 3 mg dose of Baqsimi from a new device may be administered while waiting for emergency assistance.1

There have been no studies conducted on the administration of Baqsimi and glucagon for injection, either Baqsimi followed by glucagon for injection or glucagon for injection followed by Baqsimi, to treat a single, severe hypoglycemic event. Thus, Eli Lilly and Company has no information on this usage of Baqsimi.

Enclosed Prescribing Information

BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly


1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


Baqsimi = Baqsimi™ (glucagon) nasal powder

Date of Last Review: July 24, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical